Antibodies Against the C-Terminus of ApoA-1 Are Inversely Associated with Cholesterol Efflux Capacity and HDL Metabolism in Subjects with and without Type 2 Diabetes Mellitus by Dullaart, Robin P. F. et al.
  
 University of Groningen
Antibodies Against the C-Terminus of ApoA-1 Are Inversely Associated with Cholesterol
Efflux Capacity and HDL Metabolism in Subjects with and without Type 2 Diabetes Mellitus
Dullaart, Robin P. F.; Pagano, Sabrina; Perton, Frank G.; Vuilleumier, Nicolas
Published in:
International Journal of Molecular Sciences
DOI:
10.3390/ijms20030732
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Dullaart, R. P. F., Pagano, S., Perton, F. G., & Vuilleumier, N. (2019). Antibodies Against the C-Terminus of
ApoA-1 Are Inversely Associated with Cholesterol Efflux Capacity and HDL Metabolism in Subjects with
and without Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 20(3), [732].
https://doi.org/10.3390/ijms20030732
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
 International Journal of 
Molecular Sciences
Article
Antibodies Against the C-Terminus of ApoA-1 Are
Inversely Associated with Cholesterol Efflux Capacity
and HDL Metabolism in Subjects with and without
Type 2 Diabetes Mellitus
Robin P. F. Dullaart 1,*, Sabrina Pagano 2,3 , Frank G. Perton 1 and Nicolas Vuilleumier 2,3
1 Department of Endocrinology, University Medical Center Groningen, University of Groningen,
9713 GZ Groningen, The Netherlands; f.g.perton@umcg.nl
2 Division of Laboratory Medicine, Department of Diagnostics, Hộpitaux Universitaires de Geneve,
1211 Geneva, Switzerland; Sabrina.Pagano@hcuge.ch (S.P.); Nicolas.Vuilleumier@hchuge.nl (N.V.)
3 Department of Internal Medicine Specialities, Medical Faculty, Hộpitaux Universitaires de Geneve,
1211 Geneva, Switzerland
* Correspondence: r.p.f.dullaart@umcg.nl; Tel.: +31-50-361-6161; Fax: +31-50-361-3731
Received: 22 January 2019; Accepted: 6 February 2019; Published: 9 February 2019


Abstract: Background: We determined relationships of cholesterol efflux capacity (CEC), plasma
cholesterol esterification (EST) and cholesteryl ester transfer (CET) with anti-c-terminus apoA-1
(Ac-terAA1) and anti-apolipoprotein (apo)-1 (AAA1) autoantibodies in subjects with and without
Type 2 diabetes mellitus (T2D). Methods: In 75 T2D subjects and 75 nondiabetic subjects, Ac-terAA1
and AAA1 plasma levels were measured by enzyme-linked immunosorbent assay. CEC was
measured as [3H]-cholesterol efflux from human cultured fibroblasts to diluted individual subject
plasma. Plasma EST and CET were assayed by isotope methods. Results: Ac-terAA1 and AAA1
levels and were similar between T2D and control subjects. Univariate regression analysis (n = 150)
demonstrated that Ac-terAA1 levels were inversely correlated with CEC, EST, CET, total cholesterol,
non-HDL cholesterol, triglycerides and apolipoprotein B, (p < 0.05 to p < 0.01), but not with glucose
and HbA1c. In separate multivariable linear regression models, CEC, EST and CET were inversely
associated with Ac-terAA1 levels independently of age, sex, T2D and drug use (β = −0.186, p = 0.026;
β = −0.261, p < 0.001; and β = −0.321, p < 0.001; respectively). These associations were lost after
additional adjustment for non-HDL cholesterol and triglycerides. No associations were observed
for AAA1. Conclusions: CEC, plasma EST and CET are inversely associated with Ac-terAA1
autoantibodies, conceivably attributable to an inverse relationship of these autoantibodies with
apolipoprotein B-containing lipoproteins.
Keywords: anti-apoA-1 autoantibodies; cholesterol efflux capacity; cholesterol esterification;
cholesteryl ester transfer; high-density lipoproteins; Type 2 diabetes mellitus
1. Introduction
During the past few years, evidence has accumulated that autoantibodies against high-density
lipoproteins (HDL) and its components may impact on atherothrombotic processes that play a role in
the pathogenesis of cardiovascular disease (CVD) [1]. Immunological assays to detect such antibodies
have been recently developed in several laboratories and are currently available for clinical use [2,3].
Autoantibodies of IgG subclass against apolipoprotein A-1 (AAA1), the major apolipoprotein of
HDL, have been shown to be elevated in subjects with established CVD, to be associated with
worse outcome after acute myocardial infarction and stroke, and to predict incident atherosclerotic
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CVD and overall mortality in the general population [4–9]. Furthermore, AAA1 were shown to
promote sterile inflammation in vitro and in vivo, accelerating the development of atherosclerosis
and atherothrombosis in mice [10–13]. In humans, the polyclonal AAA1 response has been shown
to be oriented against the last alpha helix of the c-terminus part of apolipoprotein A-1 (apoA-1)
(amino acids: 220–242) [14,15], and the corresponding mimetic peptide can used for both the detection
of anti-C-terminus apoA-1 (Ac-terAA1) and the neutralization of AAA1 deleterious effect in vitro [15].
Inverse associations have been observed between AAA1 levels and total cholesterol, low-density
lipoprotein cholesterol and HDL cholesterol [7,13]. These autoantibodies could, therefore, interfere
with cholesterol metabolism on top of their established proinflammatory and prothrombotic properties.
Cellular efflux of cholesterol to extracellular acceptors (cholesterol efflux capacity (CEC)) provides the
initial step in the reverse cholesterol transport (RCT) pathway, whereby cholesterol is transported back
from the arterial wall to the liver for metabolism and excretion in the bile [16–20]. CEC represents a
key metric of HDL function, and it has been suggested that impaired CEC represents an important
predictor of CVD [19,20]. HDL metabolism is a complex process regulated by a number of interdependent
pathways, starting with the generation of small lipid-poor HDL particles, i.e., pre-β-HDL, followed by
esterification of free cholesterol (EST), which results in HDL maturation, and subsequent cholesteryl
ester transfer (CET) to apolipoprotein B (apoB)-containing lipoproteins [21,22]. AAA1 and anti-HDL
antibodies have been shown to impair the antioxidant function of HDL through paraoxonase-1
inhibition [3,23–25]. Such an effect on HDL function underscores the relevance of testing the
hypothesis that AAA1 and Ac-terAA1 may interfere with CEC and HDL metabolism. Anti-apoA-1
autoantibodies have been found to be elevated in patients with Type 2 diabetes mellitus (T2D),
though particularly only in those with CVD [26]. T2D is characterized by increased plasma EST
and CET [27–29], which makes the diabetic state a relevant condition for which to interrogate the
impact of AAA1 and Ac-terAA1 on plasma EST and CET. No data are currently available concerning
the association of apoA1 autoantibodies with CEC and other metrics of HDL metabolism.
The present study was, therefore, initiated to delineate relationships of CEC, plasma EST and CET
with AAA1 and Ac-terAA1. Furthermore, we explored the possible impact of T2D on such associations
in view of abnormalities in HDL metabolism in this condition [27–29].
2. Results
The study population consisted of 75 control subjects and 75 T2D patients (Table 1). Seventeen
diabetic patients were taking sulfonylurea alone and 15 were taking metformin alone, whereas both
drugs were used by 21 patients. Antihypertensive medication (in most cases, angiotensin-converting
enzyme inhibitors, angiotensin II receptor antagonists and diuretics, alone or in combination) was
used by 29 T2D patients, but not in control subjects (p < 0.001). Oral contraceptives were taken by
4 nondiabetic women. Diabetic patients were older, more obese, had higher blood pressure and higher
fasting glucose and HbA1c levels than control subjects (Table 1). HDL cholesterol and apoA-1 were
lower in diabetic patients, coinciding with higher triglycerides. Pre-β-HDL formation was not different
between the groups, but phospholipid transfer protein (PLTP) activity, lecithin–cholesterol acylesterase
(LCAT) activity, cholesteryl ester transfer protein (CETP) mass, EST and CET were increased in T2D
patients. CEC was not different between diabetic and control subjects (Table 1). Median AAA1 and
Ac-terAA1 levels were similar between diabetic and control subjects (Table 1). As expected [15], AAA1
and Ac-terAA1 were closely correlated with each other in all subjects combined (r = 0.550, p < 0.001),
as well as in T2D patients (r = 0.549, p < 0.001) and control subjects separately (r = 0.542, p < 0.001).
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Subjects (n = 75) p-Value
Age (year) 55 ± 10 59 ± 9 0.014
Sex (M/F) 36/39 47/28 0.10
BMI (kg/m2) 25.9 ± 3.9 28.7 ± 4.9 <0.001
Systolic blood pressure (mmHg) 131 ± 20 144 ± 20 <0.001
Diastolic blood pressure (mmHg) 82 ± 11 87 ± 9 <0.001
Plasma glucose (mmol/L) 5.6 ± 0.7 8.8 ± 2.4 <0.001
HbA1c (%) 5.3 ± 0.4 6.7 ± 1.0 <0.001
Total cholesterol (mmol/L) 5.67 ± 0.98 5.40 ± 0.98 0.07
Non-HDL cholesterol (mmol/L) 4.20 ± 1.00 4.12 ± 1.07 0.65
HDL cholesterol (mmol/L) 1.49 ± 0.40 1.28 ± 0.38 0.001
Triglycerides (mmol/L) 1.31 (0.87–1.91) 1.73 (1.17–2.17) 0.036
Apolipoprotein A-1 (g/L) 1.42 ± 0.22 1.28 ± 0.38 0.030
Apolipoprotein B (g/L) 0.95 ± 0.23 0.93 ± 0.23 0.77
CEC (% per 4 h) 8.56 ± 1.00 8.66 ± 0.90 0.52
Pre-β-HDL formation (apoA-1, g/L) 0.31 ± 0.07 0.30 ± 0.07 0.31
PLTP activity (AU) 94.0 ± 10.5 103.6 ± 11.4 <0.001
LCAT activity (AU) 106.8 ± 13.1 114.1 ± 17.4 0.004
EST (nmol/mL/h) 56.1 ± 15.6 63.6 ± 18.9 0.009
CETP mass (mg/L) 2.16 ± 0.67 2.49 ± 0.90 0.011
CET (nmol/mL/h) 20.6 ± 7.5 24.1 ± 9.0 0.011
AAA1(AU) 0.35 (0.24–0.45) 0.27 (0.18–0.39) 0.16
AAc-terAA1 (AU) 0.23 (0.19–0.36) 0.22 (0.15–0.29) 0.17
Data in numbers, mean ± SD or median (interquartile range). AAA1 and Ac-terAA1 autoantibodies are expressed
as arbitrary units (AU). BMI, body mass index; CEC, cholesterol efflux capacity; CET, cholesteryl ester transfer;
CETP, cholesteryl ester transfer protein; EST, cholesterol esterification; HDL, high-density lipoprotein; LCAT,
lecithin–cholesterol acylesterase; PLTP, phospholipid transfer protein. Comparisons are done by unpaired t-tests or
Chi square analysis. Triglycerides and AUs for AAA1 and Ac-terAA1 autoantibodies are loge transformed.
Univariate regression analysis showed that in all subjects combined, Ac-terAA1 levels were
inversely correlated with total cholesterol, non-HDL cholesterol, triglycerides, apoB, LCAT activity,
EST, CET and CEC (Table 2). Similar inverse correlations between these variables and Ac-terAA1 were
found in control subjects separately, except for the correlation with CEC, which was not significant
(Table 2). These relationships did not reach significance in T2D patients separately. Notably, except
for plasma CET, for which the correlation with Ac-terAA1 levels was stronger in control subjects
than in T2D patients (p for interaction) = 0.025), there were no differences in the strength of the
correlations between T2D and control subjects (p (interaction) > 0.10 for each). No correlations were
observed between both these autoantibodies and glucose, HbA1c, HDL cholesterol, apoA-1, pre-β-HDL
formation or CETP mass (Table 2). Of further note, neither in all subjects combined nor in T2D patients
and control subjects separately were significant correlations of any of the variables listed in Table 2
with AAA1 demonstrated (Table 2).
Table 2. Associations of Ac-terAA1 and AAA1, expressed as arbitrary units (AU), with plasma
lipids, (apo)lipoproteins, pre-β-HDL, phospholipid transfer protein (PLTP) activity, lecithin–cholesterol
acylesterase (LCAT) activity, cholesterol esterification (EST), cholesteryl ester transfer protein (CETP)
mass, cholesteryl ester transfer (CET) and cholesterol efflux capacity (CEC) in all subjects combined (A)
and separately in 75 control subjects (B) and in 75 Type 2 diabetic patients (C).
A: All Subjects (n = 150) Ac-terAA1 (AU) AAA1 (AU)
Glucose −0.080 −0.127
HbA1c −0.145 −0.019
Total cholesterol −0.214 b −0.085
Non-HDL cholesterol −0.232 b −0.075
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Table 2. Cont.
A: All Subjects (n = 150) Ac-terAA1 (AU) AAA1 (AU)
HDL cholesterol 0.078 −0.014
Triglycerides −0.274 c −0.122
ApoA-1 0.017 0.001
Apo B −0.221 b −0.066
CEC −0.188 a −0.126
Pre-β-HDL formation −0.052 0.030
PLTP activity −0.072 −0.073
LCAT activity −0.197 a −0.077
EST −0.277 c −0.093
CETP mass −0.095 0.062
CET −0.324 c −0.093
B: Control Subjects (n = 75) Ac-terAA1 (AU) AAA1 (AU)
Total cholesterol −0.298 b −0.038
Glucose 0.004 −0.193
HbA1c −0.005 −0.022
Non-HDL cholesterol −0.352 c −0.035
HDL cholesterol 0.168 0.108
Triglycerides −0.449 c −0.115
ApoA-1 0.100 0.011
Apo B −0.364 c −0.042
CEC −0.l99 −0.115
Pre-β-HDL formation 0.140 −0.003
PLTP activity −0.177 0.006
LCAT activity −0.235 a −0001
EST −0.414 c 0.015
CETP mass 0.077 0.211
CET −0.535 c −0.048
C: Type 2 Diabetic Subjects (n = 75) Ac-terAA1 (AU) AAA1 (AU)
Glucose −0.006 −0.043
HbA1c −0.145 0.135
Total cholesterol −0.172 −0.179
Non-HDL cholesterol −0.130 −0.129
HDL cholesterol −0.078 −0.099
Triglycerides −0.099 −0.098
ApoA-1 −0.101 −0.054
Apo B −0.081 −0.101
CEC −0.165 −0.130
Pre-β-HDL formation 0.022 0.050
PLTP activity 0.022 −0.068
LCAT activity −0.129 −0.099
EST −0.131 −0.016
CETP mass −0.194 −0.016
CET −0.116 −0.095
Pearson correlation coefficients are shown. Triglycerides and both AAA1 and Ac-terAA1 levels are
loge transformed. a p ≤ 0.05; b p ≤ 0.02; c p ≤ 0.01.
In all subjects combined, CEC was positively correlated with pre-β-HDL formation, PLTP and
LCAT, as well as with plasma EST and CET in univariate regression analysis (Table 3). Similar
relationships were found in control subjects and T2D patients separately. CEC was unrelated to
glucose and HbA1c (Table 3). In addition, CEC was positively correlated with non-HDL cholesterol
(r = 0.450, p < 0.001), LDL cholesterol (r = 0.286, p < 0.001), apoB (r = 0.407, p < 0.001) and triglycerides
(r = 0.429, p < 0.001). Similar relationships of CE with apoB lipoproteins were found in both groups
separately (data not shown).
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Table 3. Univariate correlations of cholesterol efflux capacity (CEC) with plasma glucose,
HbA1c, pre-β-HDL formation, high-density lipoprotein (HDL) cholesterol, apolipoprotein (apo)A-1,
phospholipid transfer protein (PLTP) activity, lecithin–cholesterol acylesterase (LCAT) activity,
cholesterol esterification (EST), cholesteryl ester transfer protein (CETP) mass and cholesteryl ester
transfer (CET) in all subjects combined (A) and separately in 75 control subjects (B) and in 75 type 2
diabetic patients (C).
A: All Subjects (n = 150) CEC
Glucose 0.073
HbA1c 0.134
Pre-β-HDL formation 0.283 c
HDL cholesterol −0.089
ApoA-1 −0.056
PLTP activity 0.313 c




B: Control Subjects (n = 75) CEC
Glucose 0.086
HbA1c 0.032
Pre-β-HDL formation 0.31 b
ApoA-1 −0.005
HDL cholesterol −0.142





C: Type 2 Diabetic Subjects (n = 75) CEC
Glucose 0.052
HbA1c 0.197
Pre-β-HDL formation 0.245 a
ApoA-1 0.140
HDL cholesterol −0.001
PLTP activity 0.305 b




Pearson correlation coefficients are shown. a p ≤ 0.05; b p ≤ 0.01; c p ≤ 0.01.
We next performed multivariable linear regression analysis to disclose the independent
associations of CEC with Ac-terAA1 antibodies. This analysis included age, sex, Ac-terAA1 antibodies,
and in separate models, also pre-β-HDL formation, PLTP activity, LCAT activity and plasma EST, i.e.,
variables with which CEC was significantly correlated in univariate analysis. As shown in Table 4,
the inverse association between Ac-terAA1 and CEC was unchanged after adjusting for age, sex,
diabetes status (model 1) and additionally for the use of glucose-lowering drugs and antihypertensive
medication (model 2), as well as after additional adjustment for pre-β-HDL formation and PLTP
activity (model 3). However, this association was lost after additional adjustment for plasma EST
(Table 4, model 4). These analyses also demonstrated independent and positive associations of CEC
with pre-β-HDL formation, PLTP activity and EST.
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Table 4. Multivariable linear regression analysis showing the association of Ac-terAA1, expressed as
optical density, with cholesterol efflux capacity in 150 subjects.
Model 1 Model 2 Model 3 Model 4
β p-value β p-value β p-value β p-value
Age −0.026 0.75 −0.068 0.43 −0.121 0.13 −0.098 0.20
Sex (male vs. female) 0.157 0.23 −0.063 0.46 0.027 0.74 0.019 0.81
T2D 0.053 0.53 −0.025 0.84 −0.030 0.80 −0.027 0.81
Ac-terAA1 (AU) −0.178 0.032 −0.186 0.026 −0.157 0.044 −0.088 0.26
Pre-β-HDL formation 0.282 0.001 0.240 0.003
PLTP activity 0.245 0.007 0.185 0.003
EST 0.288 0.038
β: standardized regression coefficient. EST, cholesterol esterification; AU, arbitrary units; PLTP, phospholipid transfer
protein; T2D, Type 2 diabetes mellitus. Ac-terAA1 levels are loge transformed.
Model 1: adjusted for age, sex and diabetes status.
Model 2: adjusted for age, sex, diabetes status, and use of metformin, sulfonylurea and
antihypertensive medication.
Model 3: adjusted for age; sex; diabetes status; use of metformin, sulfonylurea and
antihypertensive medication; and pre-β-HDL formation
Model 4: adjusted for age; sex; diabetes status; use of metformin, sulfonylurea and
antihypertensive medication; pre-β-HDL formation; and plasma EST
In univariate analysis, there was a strong relationship of plasma EST with CET in all subjects
combined (r = 0.675, p < 0.001), as well as in T2D patients (r = 0.695, p < 0.001) and control subjects
separately (r = 0.695, p < 0.001). In all subjects combined, there remained a strong relationship of
plasma EST with CET after adjustment for age, sex, diabetes status, the use of glucose-lowering
drugs and antihypertensive medication, and Ac-terAA1 (β = 0.622, p < 0.001; data not shown).
Subsequently, we determined the extent to which plasma EST and CET were independently associated
with Ac-terAA1. When taking account of age, sex and diabetes status, plasma EST and CET were
still inversely and independently associated with Ac-terAA1 levels (Table 5, models 1A and B,
respectively). These inverse relationships remained significant after further adjustment for the use of
glucose-lowering drugs and antihypertensive medication (Table 5, models 2A and B), and additionally
for LCAT activity or CETP mass (Table 5, models 3A and B, respectively). Notably, the associations of
plasma EST and CET with Ac-terAA1 were lost after further adjustment for non-HDL cholesterol and
triglycerides (Table 5, models 4A and B, respectively).
Table 5. Multivariable linear regression analysis showing the association of Ac-terAA1 with plasma
cholesterol esterification (EST) (A) and plasma cholesteryl ester transfer (CET) (B) in 150 subjects.
A: EST Model 1 Model 2 Model 3 Model 4
β p-value β p-value β p-value β p-value
Age −0.058 0.47 −0.049 0.54 −0.037 0.57 0.013 0.08
Sex (male vs. female) −0.057 0.48 −0.034 0.67 −0.007 0.91 −0.065 0.26
T2D 0.205 0.012 0.010 0.93 −0.033 0.72 −0.001 0.99
Ac-terAA1 (AU) −0.252 0.002 −0.261 0.001 −0.164 0.012 −0.071 0.22
LCAT activity 0.566 <0.001 0.270 0.001
Non-HDL cholesterol −0.029 0.70
Triglycerides 0.522 <0.001
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Table 5. Cont.
B: CET Model 1 Model 2 Model 3 Model 4
β p-value β p-value β p-value β p-value
Age −0.158 0.045 −0.163 0.036 −0.154 0.045 −0.085 0.074
Sex (male vs. female) 0.067 0.39 0.095 0.21 0.120 0.12 0.031 0.97
T2D 0.195 0.015 −0.035 0.75 −0.089 0.41 0.003 0.97
Ac-terAA1 (AU) −0.308 <0.001 −0.321 <0.001 −0.312 <0.001 −0.087 0.077
CETP mass 0.207 0.008 0.141 0.004
Non-HDL cholesterol 0.313 <0.001
Triglycerides 0.506 <0.001
β: standardized regression coefficient. CET, cholesteryl ester transfer; CETP, cholesteryl ester transfer protein; EST, cholesterol
esterification; LCAT, lecithin–cholesterol acyltransferase; non-HDL, non-high-density lipoproteins; AU, arbitrary units; T2D,
Type 2 diabetes mellitus. Ac-terAA1 and triglyceride levels are loge transformed.
Model 1: adjusted for age, sex and diabetes status.
Model 2: adjusted for age, sex, diabetes status, and use of metformin, sulfonylurea and
antihypertensive medication.
Model 3: adjusted for age; sex; diabetes status; use of metformin, sulfonylurea and
antihypertensive medication; and LCAT activity (A) or CETP mass (B).
Model 4: adjusted for age; sex; diabetes status; use of metformin, sulfonylurea and
antihypertensive medication; LCAT activity (A) or CETP mass (B); non-HDL cholesterol;
and triglycerides.
3. Discussion
The present study is, to our knowledge, the first comprehensive exploration of possible AAA1
and Ac-terAA1 associations with key features of HDL metabolism in T2D patients and control
subjects. In line with other reports, T2D patients had unaltered CEC and pre-β-HDL formation,
but increased plasma PLTP activity, LCAT activity, EST, CETP mass, CET and triglycerides, together
with decreased HDL cholesterol and apoA-1 [27–29]. The first remarkable finding of our current
study is that Ac-terAA1 and AAA1 do not appear to associate in a similar fashion with parameters of
HDL metabolism. In all subjects combined, inverse associations were observed between Ac-terAA1
and total cholesterol, non-HDL cholesterol, triglycerides, apoB, CEC, plasma EST and CET, but these
associations were not observed for AAA1. Of note, Ac-terAA1 and AAA1 were not elevated in the
diabetic group, and the presence of T2D did in general not significantly modify the associations of CEC
and HDL variables with Ac-terAA1. Furthermore, as the opposite of what has been reported before for
AAA1 [7,13], no associations between Ac-terAA1, HDL cholesterol and apoA-1 levels were retrieved,
a finding which would suggest that Ac-terAA1 may impact on HDL metabolism in a different manner
compared to AAA1.
The inverse association between CEC and Ac-terAA1 levels was found to be independent of
pre-β-HDL formation, plasma PLTP and LCAT activity, but was lost when taking account of EST.
In turn, plasma EST and CET were each inversely correlated with Ac-terAA1, but these autoantibodies
were not associated with pre-β-HDL formation and PLTP activity. Remarkably, the associations of
Ac-terAA1 with EST and CET were no longer present when adjusting for plasma apoB lipoproteins,
particularly triglycerides. Furthermore, CEC was correlated positively with apoB lipoproteins. These
results are in accordance with the proposition that CEC, EST and CET are intricately coupled
processes, and reiterate the importance of apoB lipoproteins in accepting cholesteryl esters from
HDL [30]. Collectively, these results would suggest that Ac-terAA1 may impact on HDL metabolism
by influencing plasma cholesterol esterification and cholesteryl ester transfer from HDL towards
apoB-containing lipoproteins, without a major effect on ABCA1-mediated efflux via pre-β-HDL
and PLTP.
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It should be noted that at present there is no gold standard to measure CEC with respect to both
the preferred cell system and the acceptor medium. In the current study, we used cholesterol-loaded
human cultured fibroblasts as the cholesterol donor and diluted plasma from individual subjects as the
cholesterol acceptor medium. Under the experimental conditions employed, these cells abundantly
express ABCA1 [31,32]. Lipid-poor HDL particles, i.e., pre-β-HDL, and PLTP are known to stimulate
cholesterol efflux by interacting with ABCA1 [31,33,34]. In line with this, CEC was positively related to
pre-β-HDL, assayed as the formation of these particles under in vitro conditions of LCAT inhibition,
as well as to PLTP activity. Fibroblast also express the ATP-binding cassette transporter G1 (ABCG1),
but hardly any scavenger receptor class B type 1 (SR-BI), both of which are reported to interact
with mature, spherical HDL particles, although SR-BI is unlikely to mediate net cholesterol mass
efflux [33–35]. The lack of correlation of CEC with HDL cholesterol and total plasma apoA-1,
as shown in the present study, suggests that the CEC assay used here is largely independent of
ABCG1. However, the relative contribution of ABCA1, ABCG1 and aqueous diffusion to the efflux
process with human cultured fibroblasts is not well known. In addition, though still unsettled, it is
relevant to mention that CEC to diluted plasma, which contains pre-β-HDL and other relevant factors
involved in cholesterol efflux, could conceivably reflect the interaction of interstitial fluid with cells in
a different way compared to isolated HDL. In comparison, using various macrophage cell lines and
isolated patient HDL as cholesterol acceptor, CEC did correlate with HDL cholesterol and total plasma
apoA-1 [36–39]. Notably, neither in the present study including diabetic patients with predominantly
moderate hyperglycaemia, nor in our recent study evaluating CEC, determined using a macrophage
cell line and isolated HDL as cholesterol acceptor, in subjects with various degrees of glucose tolerance,
was CEC associated with glycemia. More severely hyperglycaemic circumstances could be required to
affect the cholesterol efflux process [40,41].
Although not unequivocally reported, impaired CEC may be associated with accelerated risk of
atherosclerosis development, in particular in studies in which macrophage cell lines were used as the
cholesterol donor [37,38,42]. Although the use of cultured fibroblasts to determine the association of
CEC with incident CVD is unsettled, the inverse relationship of CEC with Ac-terAA1 could imply
a proatherogenic role elicited by the presence of these autoantibodies. On the other hand, plasma
CET elevations have been shown to predict greater carotid artery intima media thickness and incident
CVD [43,44]. Increased plasma EST was also found to confer increased CVD risk, but the role of LCAT
per se in atherogenesis is still uncertain [45–48]. Translating the presently shown relationships between
Ac-terAA1 and CEC and EST and CET into CVD risk suggests a mixed picture with possible adverse
effects on CEC and beneficial effects on EST and CET.
Several other methodological issues of our study need to be discussed. We excluded subjects
using lipid-lowering drugs, since statins may affect HDL metabolism [36]. We also excluded T2D
subjects using insulin. This was done to avoid effects of insulin on CEC [49]. As a result, it is likely
that diabetic subjects with mild hyperglycaemia and mild dyslipidaemia preferentially participated,
explaining modestly elevated fasting glucose and HbA1c, as well as the lack of increase in plasma total
cholesterol and non-HDL cholesterol in the participating diabetic patients. This selection may limit
the generalizability of our findings. Furthermore, because seropositivity cutoffs for both AAA1 and
Ac-terAA1 have not been validated on ethylenediaminetetraacetic acid (EDTA) plasma, we did not
perform the analyses according to this strict criterion. Nonetheless, because AAA1 and Ac-terAA1
levels were similar between healthy controls and T2D patients, we would have expected antibody
seropositivities close to what have been retrieved in the general population. Furthermore, it is possible
that in a larger group of participants, statistically significant relationships of AAA1 and Ac-terAA1
in T2D subjects separately to CEC and HDL metabolism could have been detected. Finally, as a
consequence of case-control design of our study, no causality link can be inferred to the associations
between Ac-terAA1 and HDL metabolism.
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In conclusion, cholesterol efflux capacity, plasma cholesterol esterification and cholesteryl ester
transfer are inversely associated with Ac-terAA1, in a way that appears at least in part to be
dependent on apoB-containing lipoproteins. The mechanisms responsible for these hitherto unreported
associations await further evaluation.
4. Materials and Methods
4.1. Subjects
The study was approved by the medical ethics committee of the University Medical Centre
Groningen, The Netherlands. Subjects from north European descent aged >18 years were recruited
by advertisement. All participants provided written informed consent. T2D had been previously
diagnosed by primary care physicians using guidelines from the Dutch College of General Practitioners
(fasting plasma glucose ≥7.0 mmol/L and/or nonfasting plasma glucose ≥11.1 mmol/L). Diabetic
patients who used metformin and/or sulfonylurea were allowed to participate. We excluded patients
using insulin or other glucose-lowering drugs. The use of antihypertensive medication and oral
contraceptives was allowed. Additional exclusion criteria were clinically manifested cardiovascular
disease, renal insufficiency (estimated glomerular filtration rate <60 mL/min/1.73 m2 and/or urinary
albumin >20 mg/L), liver disease (serum transaminase levels >2 times above the upper reference
limit), pregnancy and use of lipid-lowering drugs. Current smokers and subjects who consumed >3
alcoholic drinks daily were also excluded. Physical examination did not reveal cardiac abnormalities.
Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Blood pressure
was measured after 15 min of rest at the left arm using a sphygmomanometer. The participants were
evaluated between 8 and 10 h after an overnight fast.
4.2. Laboratory Measurements
EDTA-anticoagulated plasma samples were stored at −80 ◦C until analysis. Plasma glucose was
measured shortly after blood collection with an APEC glucose analyser (APEC Inc., Danvers, MA,
USA). Glycated haemoglobin (HbA1c) was measured by high-performance liquid chromatography
(Bio-Rad, Veenendaal, The Netherlands). Plasma total cholesterol, triglycerides and HDL cholesterol
were measured using automated procedures as described. Non-HDL cholesterol was calculated as the
difference between total and HDL cholesterol. ApoA-1 and apolipoprotein B (apoB) were assayed by
immunoturbidimetry (Roche/Cobas Integra Tina-quant catalog immunoturbidimetry).
Plasma pre-β-HDL formation, i.e., the ability to generate pre-β-HDL, was measured by crossed
immunoelectrophoresis [28,50]. Briefly, samples were thawed while kept on ice. Then, 0.9 µmol/L
Pefabloc SC (Boehringer-Roche, Penzberg, Germany) and 1.8 µg/L Trasylol (Bayer, Mijdrecht,
The Netherlands) were added to inhibit proteolysis (both final concentrations). Samples were incubated
during 24 h at 37 ◦C under conditions of lecithin–cholesterol acyltransferase (LCAT) inhibition,
which was achieved by adding iodoacetate (final concentration 1.0 mmol/L) directly after thawing
the samples. The crossed immunoelectrophoresis consisted of agarose electrophoresis in the first
dimension for separation of lipoproteins with pre-β- and α-mobility. Antigen migration from the first
agarose gel into the second agarose gel, containing goat anti-human apoA-1 antiserum, was used to
quantitatively precipitate apoA1. The antiserum was monospecific for human apoA-1 using an
immunodiffusion assay. Lipoprotein electrophoresis was carried out in 1% (weight/vol) agarose gels
in Tris (80 mmol/L)–tricine (24 mmol/L) buffer, 5% (v/v) polyethylene glycol 300 (pH 8.6) and run
in an LKB 2117 system (4 ◦C for 3 h, 210 V). An amount of 3 µL plasma was added to each well.
The track of the first agarose gel was excised and annealed with melted agarose to a gel containing
0.66% (vol/vol) goat anti-human apo A-1 anti-serum (Midland Bioproducts corporation, Boone Iowa)
and 0.01% Tween 20 (weight/vol) that was cast on GelBond film (Amersham, Uppsala, Sweden).
The plate was run in an LKB 2117 system (4 ◦C for 20 h, 50 V) in Tris–tricine buffer. Unreacted antibody
was removed by extensive washing with saline. The gel was stained with Coomassie Brilliant Blue
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R250, dried and scanned with a HP Scanjet 5470c. Areas under the pre-β-HDL and α-HDL peaks
were calculated. The pre-β-HDL area was expressed as the percentage of the sum of apoA1 in the
pre-β-HDL and the α-HDL areas. Pre-β-HDL formation was calculated using the total plasma apoA1
concentration (expressed in apoA-1 (g/L)).
Plasma phospholipid transfer protein (PLTP) activity was assayed with a phospholipid
vesicles–HDL system using [14C]-labelled dipalmitoyl phosphatidylcholine [27,51]. This method
is specific for PLTP activity. PLTP activity is expressed in arbitrary units (AU; 100 AU corresponds
to 13.6 µmol phosphatidylcholine transferred per mL/h. Plasma lecithin–cholesterol acyltransferase
(LCAT) activity was determined using excess exogenous substrate containing [3H]-cholesterol [27].
Briefly, samples were incubated with labelled substrate for 6 h at 37 ◦C. Corrections were made for the
amount of free cholesterol in the samples. The reaction was stopped by adding cold ethanol to the
incubation medium. Free and esterified cholesterol were separated using disposable silica columns.
[3H]-Cholesteryl esters were eluted with hexane. LCAT activity with this assay is strongly correlated
with its plasma mass concentration [52,53]. CETP mass was measured using double-antibody sandwich
enzyme-linked immunosorbent assays [43]. Plasma CET and EST were determined as described [27–29].
To this end, [3H]-cholesterol was equilibrated for 24 h at 4 ◦C with plasma cholesterol, followed by
incubation of plasma at 37 ◦C. Thereafter, apoB-containing lipoproteins were precipitated and the
labelled cholesteryl esters were separated from labelled unesterified cholesterol on silica columns.
Plasma EST was measured as formation of cholesteryl esters after addition of [3H]-cholesterol to
plasma using the same incubation system as for the CET assay [27]. CET and EST measurements are
expressed in nmol/mL/h.
CEC was determined using human fibroblasts as cholesterol donor [28,29,32,54]. Human skin
fibroblasts were obtained from a normolipidemic control subject and were cultured (until passage 5–15)
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% v/v foetal calf serum in
24-well culture plates to full confluency. After washing them with DMEM, the cells were incubated with
[3H]-cholesterol (0.5 µCi/ mL) and unlabelled cholesterol (30 µg/mL) for 24 h in order to upregulate
ATP-binding cassette transporter A1 (ABCA1) [32]. After cholesterol loading, cells were washed three
times with phosphate buffered saline with 0.2% (weight/vol) fatty acid free bovine serum albumin.
The efflux assay was carried out by adding 1% plasma diluted in efflux medium and heparin (1.25
U/mL) to prevent clotting. After 4 h incubation at 37 ◦C, the medium was collected and centrifuged.
[3H]-Cholesterol was quantified by liquid scintillation counting. Total cellular [3H]-cholesterol was
determined after extraction of the cells with 2-propanol. CEC was calculated by dividing the radioactive
counts in the efflux medium by the sum of the counts in the medium and the cell extract. The CEC
assay was performed in duplicate. Values were corrected for appearing in the culture medium in
the absence of plasma. To be able to normalise results between series of experiments and to correct
for day-to-day variation, efflux to a human plasma pool was determined in quadruplicate. When
[14C]-cholesterol was added to the plasma-containing efflux medium, the influx rate of [14C]-cholesterol
from plasma to the cells was consistently <10% over 4 h (triplicate measurements using 3 different
plasma samples). Reuptake of newly effluxed labelled cholesterol was, therefore, considered to have
no major effect on the CEC measurements.
The inter- and intra-assay coefficients of variation (CVs) of all these assays were <9%.
AAA1and Ac-terAA1 autoantibodies were measured on EDTA plasma using our validated
enzyme-linked immunosorbent assay (ELISA) as described previously [2,4–9,12–15]. Maxisorp plates
(Nunc™, Roskilde, Denmark) were coated with purified, human delipidated apoA-1 or c-terApoA-1
(20 µg/mL; 50 µL/well) for 1 h (h) at 37 ◦C. After being washed, all wells were blocked for
1 h with 2% bovine serum albumin (BSA) in a phosphate buffer solution (PBS) at 37 ◦C. Patient
samples were additionally also added to a noncoated well in order to assess individual nonspecific
binding. After six washing cycles, 50 µL/well of signal antibody (alkaline phosphatase-conjugated
anti-human IgG; Sigma-Aldrich, St Louis, MO, USA), diluted 1:1000 in a PBS/BSA 2% solution,
was added and incubated for 1 h at 37 ◦C. After washing six more times, phosphatase substrate
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p-nitrophanylphosphate disodium (Sigma-Aldrich) dissolved in a diethanolamine buffer (pH 9.8)
was added and incubated for 20 min at 37 ◦C. Finally, optical density (OD), indicating the
immunoreactivity of the antibody, was determined at 405 nm in duplicate (Molecular DevicesTM
Versa Max). Corresponding nonspecific binding was subtracted from the mean OD for each sample to
calculate the net OD of each patient sample, which is expressed in arbitrary units (AU), as previously
validated [2,4–9,12–15]. Specificity of our ELISA to detect antibodies against native and lipid-low
human apoA1 was previously confirmed by Western blot and tandem-mass spectrometry analyses.
For these assays, the interassay CVs were 8.3% and the intra-assay CVs were 4.3%. Given the fact
that AAA1 and Ac-terAA1 seropositivity cutoffs have not been determined on plasma EDTA samples,
we only considered the continuous immunoreactivities of the antibodies [2,4–9,12–15].
4.3. Statistical Analysis
IBM SPSS software (SPSS, version 23.0, Armonk, NY: IBM Corp) was used for data analysis.
Because of skewed distribution, natural logarithm (loge)-transformed values of triglycerides and the
OD values of AAA1 and Ac-terAA1 were used. Results are expressed as mean ± SD for normally
distributed variables and as median (interquartile range) for skewed variables. Discrete variables are
given as numbers (%). Between groups differences in variables were determined by unpaired t-tests,
where appropriate using loge transformed values, or by Chi-square tests. Univariate correlations
were determined by Pearson correlation coefficients. Multivariable linear regression analyses were
carried out to disclose the independent relationships of CEC, EST and CET with clinical and laboratory
variables. Interactions were determined by calculating the product term of Ac-terAA1 OD with the
presence of T2D. Two-sided p-values < 0.05 were considered significant.
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Abbreviations
AAA1 autoantibodies against apolipoprotein A-1
ABCA1 ATP-binding cassette transporter A1
ABCG1 ATP-binding cassette transporter G1
Ac-terAA1 autoantibodies against c-terminus of apolipoprotein A-1
Apo apolipoprotein
AU arbitrary units
BMI body mass index
BSA bovine serum albumin
CEC cholesterol efflux capacity
CV coefficient of variation
CET cholesteryl ester transfer
CETP cholesteryl ester transfer protein
DMEM Dulbecco’s modified Eagle’s medium
ELISA enzyme-linked immunosorbent assay
EDTA ethylenediaminetetraacetic acid
EST cholesterol esterification




PBS phosphate buffer solution
PLTP phospholipid transfer protein
T2D Type 2 diabetes mellitus
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